Levothyroxine for solid organ donors: a review of the clinical-effectiveness and guidelines
Perras C, Clark M, Nkansah E
Record ID 32011001270
English
Authors' recommendations:
The studies identified focused on the organ donors. They did not consider clinical outcomes in the transplanted patients such as improved graft survival in the short- and long-term. One retrospective cohort study showed no difference in the number of organs procured between a donor group receiving combination hormonal therapy, a steroid group, and a control group. Another retrospective cohort study showed a statistically significant increase in the number of organs donated with the use of levothyroxine. Whether or not levothyroxine is stable in mini-bags and can be administered as an infusion has not been studied. Similarly, no information was identified on what constitutes the optimal dosing regimen of levothyroxine combined with methylprednisolone and vasopressin. Considerations for decision-making about use of levothyroxine for solid organ donors include the lack of high-quality evidence from systematic reviews or randomized controlled trials.
Details
Project Status:
Completed
Year Published:
2009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Organ Transplantation
- Thyroxine
- Tissue and Organ Procurement
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.